Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.

Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career.

In addition, Weinreich has founded multiple companies and served as a venture capitalist, board member, and biotech CEO. Weinreich joins Merck from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor.

His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Executive Medical Director, Global Product Area Leader (Angiogenesis) at Amgen.

As Global Head of R&D and Chief Medical Officer, Weinreich will lead Research and Development for the Healthcare business sector of Merck, including Medical Affairs. Weinreich brings to Merck an exceptional record of success in leading early-stage and late-stage development, with leadership responsibility in achieving approvals across the globe for multiple therapies and indications. He has extensive experience in shaping R&D strategies that deliver meaningful value to patients and drive sustainable growth for future innovation investments. He also has effectively managed large and complex pipelines and global R&D teams.

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site.